Many market reports reveal that injectable fillers will still develop and produce more in the years to come. Injectable fillers are considered as alternatives to surgery and produce temporary enhancements on the area where the procedure took place. Recent developments with Injectable and Fillers have happened for the past few months. Thus, it shows that patients prefer these non-surgical or minimally invasive cosmetic treatments.
According to news releases, a report by Technavio, the global facial injectable market will continue to dominate during its predicted forecast (2016-2022). In a similar market report by Future Market Insights, a 10-year forecast was created. Both reports disclose the brands that lead the market are Allergan and Galderma.
It seems men are more open to undertake such a procedure as well. In the report by the International Society of Aesthetic Plastic Surgery. In the US alone, there were around 622,133 procedures done for men only. It also goes for the American Society of Plastic Surgeons, which also reported that an increase for injectable fillers for men were seen in 2014. For that year, 525, 135 procedures were seen. This change could contribute to cosmetic medicine research and would see how non-cosmetic procedures proceed and develop for men in the future.
Juvederm has also had an FDA product cleared recently. Juvederm Volbella XC is the newest injectable in the Juvederm group, is a lip filler that adds volume. Many doctors are offering the new filler in their clinic months after its clearance. One of its benefits include prolonged satisfaction in lip fullness, with 62% feeling satisfied a year after the treatment. Some subjects showed side effects such as tenderness, bruising, and redness. Most of the side effects were not adverse (did not last after 30 days).